Sixth Wave Innovations - President and CEO, Dr. Jon Gluckman (left).
President and CEO, Dr. Jon Gluckman (left).
Source: Facebook.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Sixth Wave (SIXW) is preparing to commercialize its AMIPs™ testing platform as COVID-19 continues to present an ongoing concern worldwide
  • The technology has proven successful in detecting variants of the SARS-CoV-2 virus that causes Covid-19
  • Sixth Wave has already been approached by potential commercial partners seeking to deploy AMIPs in enclosed environments
  • The company plans to begin more comprehensive selectivity testing against other respiratory viruses and bacteria starting in January
  • Sixth Wave is a nanotechnology company
  • Shares in Sixth Wave (SIXW) are up 6.38 per cent, trading at $0.25 per share

Sixth Wave (SIXW) is preparing to commercialize its AMIPs™ testing platform as COVID-19 continues to present an ongoing concern worldwide.

Right now, the company is in the process of testing the technology using live viruses in saliva samples. It expects to complete that work in Q2 of 2022 and submit results and the AMIPs platform to a third party for validation.

The technology has proven successful in detecting variants of the SARS-CoV-2 virus that causes Covid-19. Similar testing will begin on the highly transmissible Omicron variant as soon as virus samples become available.

Sixth Wave has already been approached by potential commercial partners seeking to deploy AMIPs in sensors to monitor enclosed environments for the presence of the virus.

From sports stadiums to theatres, office buildings to schools and hospitals, there is a massive need for real-time testing to alert people to a heightened risk of disease.

Sixth Wave is now engaged with four potential partners to commercialize the AMIPs platform. Working with a device manufacturing partner, the company could have an AMIPs-based product ready for field testing in six months under the right conditions.

The company plans to begin more comprehensive selectivity testing against other respiratory viruses and bacteria starting in January 2022.

Dr. Jonathan Gluckman, President and CEO of Sixth Wave, commented on the progress.

“The accelerated timeline for this accomplishment is a testament to the underlying technology platform we have developed over a number of years,” he said. “We are confident that our advances toward commercialization are foundational and will benefit the use the AMIPS platform in delivering a diversity of future virus detection products.”

Sixth Wave is a nanotechnology company with patented technologies that focus on extraction and detection of target substances at the molecular level.

Shares in Sixth Wave (SIXW) are up 6.38 per cent, trading at $0.25 per share as of 11:50 am EST.

More From The Market Herald
GameOn - Founder and CEO, Matt Bailey.

" GameOn (CSE:GET) receives US$560,000 loan

GameOn Entertainment Technologies (GET) has obtained a US$560,000 loan from Proje Ventures Inc. 
Knight Therapeutics - President and CEO, Samira Sakhia.

" Knight Therapeutics (TSX:GUD) relaunches AKYNZEO in Brazil

Knight Therapeutics’ (GUD) affiliate United Medical has relaunched AKYNZEO in Brazil.

" RIWI Corp. (TSXV:RIWI) acquires Research on Mobile

RIWI Corp. (RIWI) has completed its previously announced acquisition of Research on Mobile (ROM).

" Record revenue for California Nanotechnologies (TSXV:CNO) fiscal 2022

California Nanotechnologies (CNO) announced record revenues of US$1,081,500 for the year ending February 28, 2022, a 39 per cent increase from last year.